Last 35 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Xeris Biopharma Holdings, Inc.'s quarterly P/E stands at 115.1x. EV/EBITDA has compressed 99.6% YoY to 21.5x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 2312.50 | 115.08 | 31.91 | 678.33 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.38 | 3.10 | 4.12 | 4.86 | 2.55 | 3.48 | 2.10 | 1.96 | 1.74 | 1.91 | 1.83 | 1.33 | 2.37 |
| — | -11.0% | +95.9% | +148.4% | +46.6% | +82.2% | +15.0% | +47.2% | -26.6% | +13.5% | +34.0% | -25.5% | +14.8% | |
| P/B Ratio | 93.38 | 79.18 | 103.26 | — | — | — | — | — | — | — | — | 66.44 | 26.38 |
| — | — | — | — | — | — | — | — | — | — | — | +1624.3% | +834.5% | |
| P/FCF | 45.74 | 26.98 | 17.93 | 20.00 | — | — | 72.00 | — | — | — | 13.19 | — | — |
| — | — | -75.1% | — | — | — | +446.0% | — | — | — | — | — | — | |
| EV / EBITDA | 32.50 | 21.48 | 16.91 | 35.09 | 30.29 | 4939.81 | 36.64 | — | — | — | — | — | — |
| — | -99.6% | -53.9% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 48.37 | 30.19 | 30.24 | 44.12 | 42.65 | — | 68.07 | — | — | — | — | — | — |
| — | — | -55.6% | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Xeris Biopharma Holdings, Inc.'s operating margin was 9.5% in Q1 2026, down 10.0 pp QoQ and up 14.7 pp YoY. The trailing four-quarter average of 11.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.7% | 84.0% | 77.8% | 85.2% | 79.6% | 85.5% | 84.2% | 75.0% | 78.2% | 85.3% | 76.8% | 83.0% | 80.1% |
| — | -1.7% | -7.7% | +13.7% | +1.8% | +0.2% | +9.6% | -9.7% | -2.5% | +1.6% | -5.2% | +0.9% | -1.1% | |
| Operating Margin | 8.5% | 9.5% | 19.5% | 9.0% | 6.3% | -5.1% | 2.8% | -23.8% | -17.0% | -35.1% | -22.2% | -10.2% | -42.0% |
| — | +285.3% | +599.7% | +138.1% | +136.8% | +85.3% | +112.6% | -133.7% | +59.5% | +12.4% | +51.6% | +83.9% | +43.8% | |
| Net Margin | 0.2% | 2.7% | 12.9% | 0.8% | -2.7% | -15.3% | -8.5% | -29.0% | -31.2% | -46.7% | -30.2% | -25.2% | -52.2% |
| — | +117.5% | +251.8% | +102.9% | +91.4% | +67.2% | +71.8% | -15.0% | +40.2% | +7.9% | +22.7% | +65.7% | +49.5% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.0% | 16.7% | 172.8% | — | — | — | — | — | — | — | — | -139.3% | -90.8% |
| — | — | — | — | — | — | — | — | — | — | — | -311.4% | -195.5% | |
| ROA | 0.2% | 0.6% | 2.9% | 0.2% | -0.6% | -2.9% | -1.6% | -4.8% | -4.5% | -5.8% | -4.1% | -3.7% | -6.1% |
| — | +119.9% | +285.2% | +103.7% | +86.8% | +49.8% | +61.4% | -29.9% | +26.4% | -13.9% | -3.1% | +47.1% | +23.5% | |
| ROIC | 33.8% | — | — | 8.1% | 1.9% | -1.3% | 0.7% | -5.1% | -3.2% | -6.1% | -4.3% | -1.9% | -6.5% |
| — | — | — | +258.0% | +160.3% | +77.9% | +116.4% | -163.7% | +51.4% | +8.9% | +56.1% | +84.4% | +43.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Xeris Biopharma Holdings, Inc.'s Debt/EBITDA ratio is 3.4x, up from 1.9x last quarter — at a moderate level that warrants monitoring. The current ratio has improved 23.4% YoY to 2.12x, strengthening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.76 | 2.87 | 2.76 | — | — | — | — | — | — | — | — | 58.98 | 16.49 |
| — | — | — | — | — | — | — | — | — | — | — | +2243.6% | +783.3% | |
| Debt / EBITDA | 1.02 | 3.36 | 1.91 | 3.85 | 33.64 | 5070.77 | 56.41 | — | — | — | — | — | — |
| — | -99.9% | -96.6% | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.19 | 2.12 | 2.19 | 1.93 | 1.95 | 1.72 | 1.67 | 1.79 | 2.26 | 2.37 | 1.64 | 1.82 | 1.95 |
| — | +23.4% | +31.4% | +7.8% | -13.6% | -27.5% | +1.7% | -1.5% | +15.4% | +16.6% | -35.3% | -16.4% | -21.7% | |
| Quick Ratio | 1.57 | 1.50 | 1.57 | 1.35 | 1.24 | 1.17 | 1.19 | 1.29 | 1.69 | 1.81 | 1.23 | 1.38 | 1.50 |
| — | +28.4% | +31.7% | +4.2% | -26.3% | -35.7% | -3.6% | -6.1% | +12.8% | +8.1% | -44.0% | -26.7% | -32.6% | |
| Interest Coverage | 0.02 | 1.15 | 1.55 | 1.09 | 0.74 | -0.26 | 0.34 | -1.45 | -0.79 | -1.66 | -0.94 | -0.83 | -2.14 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XERS stock.
Xeris Biopharma Holdings, Inc.'s current P/E is 2312.5x. The average P/E over the last 3 quarters is 275.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Xeris Biopharma Holdings, Inc.'s current operating margin is 8.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Xeris Biopharma Holdings, Inc.'s business trajectory between earnings reports.